A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie zaawansowany rak (niemożliwy do operacji, rozprzestrzeniający się lub z przerzutami) lub chłoniak, który wrócił po leczeniu
- •Choroba pogorszyła się, wznowiła się lub pacjent nie toleruje standardowego leczenia przeciwnowotworowego
- •Dobry stan ogólny (zdolność do codziennych czynności)
- •Widoczne zmiany nowotworowe potwierdzone tomografią lub rezonansem magnetycznym
✗ Disqualifies
- •Wcześniejsze leczenie innym podobnym lekiem degradującym RBM39
- •Poważne problemy z trawieniem lub wchłanianiem leków
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
City of Hope
Duarte, United States
Sarcoma Oncology Research Center
Santa Monica, United States
Cleveland Clinic
Cleveland, United States
SCRI Oncology Partners - PPDS
Nashville, United States
START Mountain Region
West Valley City, United States
Princess Margaret Cancer Centre
Toronto, Canada
McGill University Health Centre (MUHC) - The Montreal
Québec, Canada
Trial contact
Mihae Song
Victoria Chua
Jessica Grenbenc
Marie Asay
Anh Nguyen
Phuong-nam Nguyen
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.